Younger women at risk of losing bone mass and bone quality are now officially one group who should be screened for osteoporosis with bone density scans, according to updated U.S. Preventive Services Task Force (USPSTF) recommendations.
The administration of abaloparatide (Tymlos) for 18 months followed by alendronate (Fosamax) for 2 years was associated with dramatic reductions in fracture risk among postmenopausal women, according to researchers here.
A new genetic screen may predict the risk of osteoporosis and bone fracture, according to a researcher at Stanford University School of Medicine in California.
New developments with the FDA and new scientific findings are adding momentum to two drugs experts believe are game-changers in osteoporosis treatment.
Osteoporosis affects more than 200 million people worldwide, with a higher prevalence in women compared with men.1 In the United States, the estimated prevalence is 10.3% in adults aged 50 years and older, and an additional 43.9% of this population has been shown to have low bone mass.
About 54 million Americans have osteoporosis or are at high risk because of low bone mass. Roughly one in two women and up to one in four men age 50 and older will break a bone because they have osteoporosis.
AUSTIN, Texas -- While most clinicians agree that vitamin D can play a role in treating osteoporosis, how large a role, how much and for what types of patients are still heavily debated topics, one expert said.
High-intensity resistance and impact training (HiRIT) improved bone mineral density and physical strength in postmenopausal women with low bone mass, without causing any fractures, researchers reported.